Daily ED treatment is not simply a lighter version of an on-demand erectile dysfunction pill. It is a different treatment model with a different clinical aim. Instead of creating a short pharmacologic peak around a planned sexual encounter, a daily regimen attempts to maintain a steadier physiologic background for men whose symptoms are frequent enough that timing itself becomes part of the problem. That approach can be reasonable, but only when the formulation is judged by mechanism, patient selection, and evidence rather than by the assumption that more ingredients automatically mean better outcomes.
Daily ED Treatment Changes the Goal of Therapy
Standard on-demand PDE5 inhibitor treatment is built around an event. A man takes the medication, waits for absorption, and expects a defined therapeutic window. For many patients that works well. For others, it introduces familiar friction, including planning pressure, inconsistent response after heavy meals or alcohol, and the sense that intimacy has to be organized around dosing.
Daily treatment addresses a different problem. It tries to reduce the gap between medication timing and sexual readiness by keeping some level of PDE5 inhibition present more consistently. That model can make sense when erectile dysfunction reflects a broader vascular or metabolic pattern, including endothelial dysfunction, insulin resistance, hypertension, central adiposity, poor sleep, or mixed contributors rather than a purely situational issue.
There is also a practical reason daily regimens matter. A 2025 cross-sectional study of 233 men using tadalafil 5 mg once daily found acceptable adherence overall, but showed that adherence still depended heavily on beliefs about treatment, socioeconomic context, and ongoing follow-up [1]. In other words, daily therapy is not just a pharmacologic decision. It is a behavior-dependent treatment model that works best when the patient understands what the regimen is trying to accomplish.
Why Tadalafil and Vardenafil Are Used Differently in a Maintenance Formula
A low-dose daily formula that includes tadalafil and vardenafil should not be understood as the equivalent of taking two higher-dose on-demand drugs at once. The pharmacologic logic is narrower than that. Tadalafil is the better-established maintenance component because its long half-life allows sustained exposure after once-daily dosing. That property is the reason it anchors most daily-treatment literature.
Vardenafil behaves differently, with a shorter half-life and a different onset profile. In a supervised low-dose formula, the rationale for including it is not that dual-PDE5 therapy has been proven broadly superior in all men. It is that a second low-dose PDE5 inhibitor may add a somewhat different pharmacodynamic profile without relying on a single agent to create a higher peak. That is a formulation hypothesis, not a blanket efficacy claim.
That distinction matters because the evidence base is much stronger for standard single-agent PDE5 therapy than for routine unsupervised dual-PDE5 use. The most defensible clinical position is therefore modest: tadalafil provides the core maintenance framework, while low-dose vardenafil may broaden coverage in selected patients under physician supervision.
What the Recent Daily-Tadalafil Literature Actually Shows
The best contemporary evidence in this category still centers on tadalafil. In a 2024 placebo-controlled study published in International Urology and Nephrology, tadalafil 5 mg daily improved erectile function when delivered either as a conventional tablet or as an oral dispersible film in men with mild-to-moderate erectile dysfunction [2]. The dispersible format also performed well on tolerability and compliance measures. That does not prove that every chewable or fast-dissolving formulation is inherently better, but it supports the broader idea that daily tadalafil remains effective across alternative oral formats.
A second 2024 randomized study compared daily tadalafil 5 mg with daily sildenafil 25 mg and found that both improved erectile function, while tadalafil was associated with larger reductions in inflammatory markers such as neutrophil-lymphocyte and platelet-lymphocyte ratios [3]. Those biomarkers should not be over-interpreted, but the study does reinforce the larger concept that daily PDE5 therapy may interact with vascular and inflammatory biology rather than functioning only as a short-term performance aid.
Longer-term comparative evidence points in the same direction. A 2019 meta-analysis of long-term studies found that tadalafil once daily produced slightly better erectile-function outcomes and fewer treatment-emergent adverse effects than tadalafil on demand after at least 24 weeks of use [4]. Although that meta-analysis is not recent, it remains relevant because it helps explain why once-daily tadalafil continues to occupy a distinct place in ED management.
Where Vitamin D3 and K2 Fit, and Where the Evidence Is Thinner
The nutrient layer in a daily men’s-health formula requires more caution than the PDE5 layer. Vitamin D is the more plausible erectile-function adjunct because deficiency is common and because lower vitamin D status has repeatedly been associated with worse endothelial health, worse cardiometabolic risk, and more severe erectile symptoms in observational research.
A 2025 systematic review in the Journal of Clinical Medicine concluded that lower vitamin D levels were consistently associated with more severe erectile dysfunction across observational studies, while also emphasizing that the certainty of the evidence remains limited and intervention findings are mixed [5]. That is an important distinction. Association is not the same as treatment effect.
Recent interventional and genetic data make that limitation clearer. In the 2024 randomized placebo-controlled D-Health Trial, three years of vitamin D supplementation markedly increased serum vitamin D levels but did not reduce erectile dysfunction prevalence in an unselected older male population [6]. In the same year, a Mendelian randomization study did not support a clear causal relationship between genetically predicted vitamin D levels and ED risk [7]. Taken together, those results argue against presenting vitamin D as a stand-alone erectile dysfunction treatment.
Vitamin K2 is more indirect still. Its rationale is tied to vascular biology and calcium handling rather than to direct clinical trials showing improved erectile outcomes. For that reason, the cleanest evidence-based framing is that vitamin D3 and K2 may be reasonable supportive additions in a physician-designed daily formula, especially when deficiency, diet quality, or vascular-risk context matters, but they should not be presented as the main source of erectile benefit.
Who This Kind of Formula May Fit Best
A daily low-dose formula is most likely to fit men whose symptoms are frequent enough that on-demand dosing feels cumbersome, men who want less timing pressure, or men whose erectile dysfunction appears to sit inside a larger vascular-health picture. That includes men with hypertension, abdominal adiposity, insulin resistance, sleep disruption, or mixed cardiometabolic risk factors.
There is also a broader systems-level reason to interpret ED in that context. In a 2025 observational analysis involving more than 500,000 men with erectile dysfunction, Jehle and colleagues reported that tadalafil and sildenafil use were associated with lower risks of all-cause mortality, cardiovascular disease, and dementia, with tadalafil showing the stronger signal in several comparisons [8]. This does not mean PDE5 inhibitors should be prescribed for prevention, and it certainly does not prove causality. It does, however, reinforce an important clinical idea: erectile-function treatment belongs within vascular medicine, not outside it.
The same formula is less likely to fit men with infrequent symptoms, men who already do well with standard on-demand therapy, or men who are tempted to combine prescribed daily medication with extra unsupervised PDE5 use. The strength of a maintenance regimen comes from predictability and oversight, not from improvisation.
How to Take It and What to Watch
A daily regimen only works as intended if it is actually taken daily. In practical terms, that means once per day at roughly the same time, not only on anticipated sexual-activity days. It also means expectations have to be different from the expectations surrounding an on-demand pill. Men should not judge the regimen by a single encounter. The relevant timeframe is usually days to weeks, not one isolated dose.
Monitoring should include more than erection quality alone. Headache, flushing, dyspepsia, congestion, dizziness, blood-pressure context, medication interactions, and accidental dose stacking all matter. So does the larger clinical picture. If erectile dysfunction is persistent, progressive, associated with loss of morning erections, or accompanied by chest symptoms, poor exercise tolerance, urinary changes, or major libido changes, that is not a signal to keep adding medication. It is a signal to reassess the underlying cause.
Conclusion
Daily ED treatment can be clinically sensible when the goal is a steadier baseline with less timing pressure rather than a short-lived pharmacologic peak. The evidence is strongest for the tadalafil component and for the broader idea that erectile dysfunction should be viewed through vascular and metabolic health, not performance alone. Low-dose vardenafil may add a complementary pharmacologic profile in a supervised formula, while vitamin D3 and K2 are better understood as supportive components than as primary erectile dysfunction therapies. The most evidence-based summary is that this kind of regimen may suit selected men well, but the formulation should be judged by realistic expectations, physician screening, and honest discussion of what is known versus what is inferred.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. Related education is available in the blog, and physician-supervised formulation details are available here.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Kandemir O, Altinbas NK, Aydin A, et al. Assessing Medication Adherence to Tadalafil 5 mg Once Daily in Erectile Dysfunction: A Cross-Sectional Analysis. Pharmacology Research & Perspectives. 2025;13(3):e70129. doi:10.1002/prp2.70129
- Motawi AT, GamalEl Din SF, Meatmed EM, Fahmy I. Evaluation of efficacy and safety profile of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film in men with mild-to-moderate erectile dysfunction: a comparative placebo-controlled study. International Urology and Nephrology. 2024;56:2531-2537. doi:10.1007/s11255-024-04003-x
- Bakry AR, Mahran AM, Gaber HD, Sedek MI, GamalEl Din SF, Motawi AT, Mohamed MD, Elshebany A. Evaluation of the effect of daily tadalafil 5 mg versus daily sildenafil 25 mg on neutrophil-lymphocyte and platelet-lymphocyte ratios in patients with erectile dysfunction: a comparative randomized controlled study. Archivio Italiano di Urologia e Andrologia. 2024;96(4):12756. doi:10.4081/aiua.2024.12756
- Zhou Z, Chen H, Wu J, Wang J, Zhang X, Ma J, Cui Y. Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction. Sexual Medicine. 2019;7(3):282-291. doi:10.1016/j.esxm.2019.06.006
- Matukaitienė R, Žukauskienė R, Kasparavičius J, et al. The Association Between Vitamin D Levels and Erectile Dysfunction in Men: A Systematic Review. Journal of Clinical Medicine. 2025;14(24):8630. doi:10.3390/jcm14248630
- Duarte Romero B, Waterhouse M, Baxter C, McLeod DSA, English DR, Armstrong BK, Chung E, Ebeling PR, Hartel G, van der Pols JC, et al. The effect of three years of vitamin D supplementation on erectile dysfunction: Results from the randomized placebo-controlled D-Health Trial. Clinical Nutrition ESPEN. 2024;60:109-115. doi:10.1016/j.clnesp.2024.01.011
- Sun H, Shen G, Dong H, Shang M, Zhou W, Wang L, Li Z, Gong J, Hu B. Serum 25-hydroxyvitamin D level and erectile dysfunction: a causal relationship? Findings from a two-sample Mendelian randomization study. Frontiers in Molecular Biosciences. 2024;11:1390814. doi:10.3389/fmolb.2024.1390814
- Jehle DVK, Sunesra R, Uddin H, Paul KK, Joglar AA, Michler OD, Blackwell TA, Gaalema D, Hayek S, Jneid H. Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia. The American Journal of Medicine. 2025;138(3):441-448.e3. doi:10.1016/j.amjmed.2024.10.039
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.